FDA Approves Lilly’s Once-Weekly Insulin Onswik, Challenging Novo’s Awiqli

FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.